Department of Neurosciences, Sakra World Hospital, Bellandur, Bangalore, Karnataka, India.
Department of Neurosciences, Sakra World Hospital, Bellandur, Bangalore, Karnataka, India.
World Neurosurg. 2019 May;125:253-256. doi: 10.1016/j.wneu.2019.02.003. Epub 2019 Feb 18.
Rosette-forming glioneuronal tumour [RGNT] is a relatively rare entity first identified as a separate entity in 2002. We are reporting the second case of RGNT in the opticochiasmatic region.
We report a case report and literature review of RGNT with syndromic association.
Although initial reports were predominantly in the fourth ventricle, many recent reports have identified the possibility of its occurrence outside fourth ventricle in pineal gland, spinal cord, septum pellucidum, lateral ventricle, and suprasellar region. To date, only 1 case of RGNT involving the opticochiasmatic region has been reported in a patient with neurofibromatosis type 1. Genetic analysis of this rare tumor identified 3 hotspots involving somatic mutations of FGFR-1 and PIK3CA and a germline mutation involving PTPN11, which can be targets for therapeutic intervention in cases where complete resection is not possible. To the best of our knowledge, we report the first case of RGNT involving the opticochiasmatic region without any syndromic association. Other cases of RGNT with syndromic associations provide us with insight into possible therapeutic interventions.
玫瑰花结形成的神经胶质神经元肿瘤(RGNT)是一种相对罕见的实体肿瘤,于 2002 年首次被确定为一种独立的实体肿瘤。我们报告了发生在视交叉区域的第二例 RGNT 病例。
我们报告了一例伴有综合征关联的 RGNT 病例,并进行了文献复习。
尽管最初的报告主要集中在第四脑室,但许多最近的报告已经确定了它在第四脑室以外的松果体、脊髓、透明隔、侧脑室和鞍上区域发生的可能性。迄今为止,只有 1 例 RGNT 累及视交叉区域的病例发生在 1 型神经纤维瘤病患者中。对这种罕见肿瘤的基因分析确定了 3 个热点,涉及 FGFR-1 和 PIK3CA 的体细胞突变,以及涉及 PTPN11 的种系突变,这可能成为无法完全切除病例的治疗干预靶点。据我们所知,我们报告了首例无综合征关联的视交叉区域 RGNT 病例。其他伴有综合征关联的 RGNT 病例为我们提供了可能的治疗干预措施的深入了解。